Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
出版年份 2021 全文链接
标题
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
作者
关键词
-
出版物
Cancers
Volume 13, Issue 19, Pages 4820
出版商
MDPI AG
发表日期
2021-09-27
DOI
10.3390/cancers13194820
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
- (2021) Priyanka Singh et al. MEDICAL ONCOLOGY
- Lonafarnib: First Approval
- (2021) Sohita Dhillon DRUGS
- Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
- (2021) Tariq I. Mughal et al. HAEMATOLOGICA
- PKC‐β/Alox5 axis activation promotes Bcr‐Abl‐independent TKI‐resistance in chronic myeloid leukemia
- (2021) Dan Ma et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- (2021) Valentín Garcia-Gutiérrez et al. Blood Cancer Journal
- Third-line therapy for chronic myeloid leukemia: current status and future directions
- (2021) Jorge Cortes et al. Journal of Hematology & Oncology
- Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
- (2021) Ya-Ching Hsieh et al. LEUKEMIA
- Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
- (2021) Hui Mu et al. Frontiers in Oncology
- Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
- (2021) Sylwester Głowacki et al. Biomolecules
- A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data
- (2021) Ronald G Hauser et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
- (2021) Meike Kaehler et al. Frontiers in Pharmacology
- Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
- (2021) P Torres-Barrera et al. Current Research in Translational Medicine
- Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
- (2021) Paulina Kwaśnik et al. Journal of Personalized Medicine
- Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making
- (2020) Simona Soverini et al. BLOOD
- Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications
- (2020) Paula Sabbo Bernardo et al. BLOOD REVIEWS
- DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
- (2020) Popp et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance
- (2020) Zi-Yuan Nie et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
- (2020) Seda Baykal-Köse et al. PLoS One
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
- (2020) Abhishek Maiti et al. ACTA HAEMATOLOGICA
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
- (2020) Tun Kiat Ko et al. BLOOD
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors
- (2020) Katharina Rothe et al. Cell Stem Cell
- A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
- (2020) Maro Ohanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
- (2020) Andreas Hochhaus et al. LEUKEMIA
- Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
- (2020) Rahul Kumar et al. LEUKEMIA
- Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
- (2020) Cosimo Cumbo et al. Cancer Management and Research
- Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
- (2020) Jan Stetka et al. Cancers
- Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations
- (2020) Monica M. Arroyo et al. Biomolecules
- MDM2 inhibition: an important step forward in cancer therapy
- (2020) Marina Konopleva et al. LEUKEMIA
- Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2020) Michael W. Deininger et al. Journal of the National Comprehensive Cancer Network
- Declaration of Bcr-Abl1 independence
- (2020) Helong Zhao et al. LEUKEMIA
- The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
- (2020) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors
- (2020) Xiaoyan Zhang et al. Stem Cells International
- Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
- (2020) Simona Soverini et al. Journal of Clinical Medicine
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia
- (2019) Ramachandran Krishna Chandran et al. Frontiers in Oncology
- Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia
- (2019) Raquel Alves et al. MEDICAL ONCOLOGY
- Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
- (2019) Puneet Agarwal et al. Cell Stem Cell
- Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
- (2019) Daniel Nisakar Meenakshi Sundaram et al. DRUG DISCOVERY TODAY
- Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms
- (2019) Bruno A. Cardoso et al. EXPERIMENTAL HEMATOLOGY
- PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
- (2019) Ekaterina Ivanova et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA
- (2019) Justin T. Brown et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
- (2019) Aytug Kizilors et al. Lancet Haematology
- Recommandations du France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) pour l’examen des mutations du domaine kinase de BCR-ABL1 dans la leucémie myéloïde chronique
- (2019) Jean-Michel Cayuela et al. BULLETIN DU CANCER
- SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
- (2019) Ajay Abraham et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL
- (2019) Jiu-Yu Zhan et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- MicroRNA signature refine response prediction in CML
- (2019) Raquel Alves et al. Scientific Reports
- Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
- (2019) Ipsita Pal et al. Current Hematologic Malignancy Reports
- Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
- (2019) Michael J Reff et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
- (2019) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- Machine learning applications in the diagnosis of leukemia: Current trends and future directions
- (2019) Haneen T. Salah et al. International Journal of Laboratory Hematology
- The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia
- (2019) Hui Xu et al. LEUKEMIA & LYMPHOMA
- The FoxO–Autophagy Axis in Health and Disease
- (2019) Zhiyong Cheng TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2019) Marjan Yaghmaie et al. Current Hematologic Malignancy Reports
- New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
- (2019) Peter E. Westerweel et al. Frontiers in Oncology
- Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia
- (2019) Manon Lernoux et al. BIOCHEMICAL PHARMACOLOGY
- Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
- (2019) Zachariah DeFilipp et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Metabolic dependencies and vulnerabilities in leukemia
- (2019) Marissa Rashkovan et al. GENES & DEVELOPMENT
- Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
- (2019) Fabien Muselli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
- (2019) Xuechao Liu et al. Cell and Bioscience
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
- (2019) Simona Soverini et al. BLOOD
- Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
- (2019) Luana Bavaro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
- (2018) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease
- (2018) Sanjay K. Nigam Annual Review of Pharmacology and Toxicology
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
- (2018) Sébastien Rinaldetti et al. Clinical Lymphoma Myeloma & Leukemia
- Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium
- (2018) Sook Wah Yee et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Venetoclax: A new wave in hematooncology
- (2018) Jana Mihalyova et al. EXPERIMENTAL HEMATOLOGY
- The bone marrow microenvironment in health and disease at a glance
- (2018) Rahul Kumar et al. JOURNAL OF CELL SCIENCE
- Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
- (2018) Federico Rossari et al. Journal of Hematology & Oncology
- Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
- (2018) Oscar Brück et al. LEUKEMIA
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
- (2018) Michele Massimino et al. Molecular Cancer
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
- (2018) Raquel Maia et al. MOLECULES
- ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
- (2018) Laura N. Eadie et al. PLoS One
- A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
- (2018) Su-In Lee et al. Nature Communications
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
- (2018) Elena Arrigoni et al. Stem Cells Translational Medicine
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
- (2018) Maro Ohanian et al. Lancet Haematology
- Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia
- (2018) Sabrina Inselmann et al. CANCER RESEARCH
- Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function and drug pharmacokinetics
- (2018) Niall Heyes et al. DRUG METABOLISM AND DISPOSITION
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
- (2018) Klara Srutova et al. HAEMATOLOGICA
- Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients
- (2018) Siti Maziras Makhtar et al. JOURNAL OF GENETICS
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
- (2018) Pablo Baquero et al. LEUKEMIA
- Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
- (2018) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
- (2018) Tatjana Bilich et al. BLOOD
- Nilotinib in the treatment of chronic myeloid leukemia
- (2018) Tomasz Sacha et al. Future Oncology
- A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
- (2018) Kendra Sweet et al. LEUKEMIA RESEARCH
- Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance
- (2018) Vivek Kumar Singh et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
- (2017) Giovanni Luca Beretta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Epigenetic dysregulation of hematopoietic stem cells and preleukemic state
- (2017) Hiroyoshi Kunimoto et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
- (2017) Naofumi Mukaida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
- (2017) Ziyuan Lu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
- (2017) Ayuna Hattori et al. NATURE
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- Remembrance of things past — discontinuation of second-generation TKI therapy for CML
- (2017) Timothy P. Hughes et al. Nature Reviews Clinical Oncology
- Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
- (2017) Zhi-Ping Jiang et al. PHARMACOGENOMICS
- Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
- (2017) E Togasaki et al. Blood Cancer Journal
- Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System
- (2017) Haneen Banjar et al. Biomed Research International
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
- (2017) Amy Hughes et al. Frontiers in Immunology
- Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
- (2016) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3′-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2
- (2016) Anne Ripperger et al. BIOCHEMICAL PHARMACOLOGY
- Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
- (2016) TaeHyung Kim et al. BLOOD
- Somatic mosaicism in chronic myeloid leukemia in remission
- (2016) K. Mitani et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
- (2016) Philippe Rousselot et al. CANCER
- miR-146b-5p within BCR-ABL1-Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells
- (2016) H.-M. Zhang et al. CANCER RESEARCH
- ABC transporters as mediators of drug resistance and contributors to cancer cell biology
- (2016) Jamie I. Fletcher et al. DRUG RESISTANCE UPDATES
- Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
- (2016) Lisa Pleyer et al. Journal of Hematology & Oncology
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
- (2016) L N Eadie et al. LEUKEMIA
- Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
- (2016) Juan Eduardo Megías-Vericat et al. LEUKEMIA & LYMPHOMA
- Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 35INS
- (2016) Ellin Berman et al. LEUKEMIA RESEARCH
- Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice
- (2016) Flavia da Cunha Vasconcelos et al. LEUKEMIA RESEARCH
- MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells
- (2016) Tsung-Yao Lin et al. PLoS One
- Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation
- (2016) Y. Taya et al. SCIENCE
- Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
- (2016) Claudia Neul et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
- (2016) S Harrach et al. Blood Cancer Journal
- MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
- (2016) Chiranjib Chakraborty et al. Oncotarget
- Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells
- (2016) S. Agatheeswaran et al. Scientific Reports
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
- (2016) Lauren Caldemeyer et al. Current Hematologic Malignancy Reports
- ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
- (2016) Laura N. Eadie et al. PLoS One
- Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
- (2015) W. Wang et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- The dynamics of adult haematopoiesis in the bone and bone marrow environment
- (2015) Miriel S. H. Ho et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia
- (2015) Shantashri Vaidya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)
- (2015) Silvia Marcé et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
- (2015) Fatima Dkhissi et al. EXPERIMENTAL HEMATOLOGY
- Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
- (2015) Marialuisa Polillo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- Drug transporters play a key role in the complex process of Imatinib resistance in vitro
- (2015) Raquel Alves et al. LEUKEMIA RESEARCH
- Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
- (2015) Gregor Hoermann et al. MEDIATORS OF INFLAMMATION
- Structure and function of Gab2 and its role in cancer (Review)
- (2015) CHEN-BO DING et al. Molecular Medicine Reports
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
- (2015) Kazuhito Naka et al. Nature Communications
- The physiological role of drug transporters
- (2015) Yu Liang et al. Protein & Cell
- Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
- (2015) Shantashri Vaidya et al. PLoS One
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- Epigenetic drugs against cancer: an evolving landscape
- (2014) Antonella Di Costanzo et al. ARCHIVES OF TOXICOLOGY
- Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients
- (2014) Anthony Au et al. BIOMEDICINE & PHARMACOTHERAPY
- ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance
- (2014) A.F. Ferreira et al. BLOOD CELLS MOLECULES AND DISEASES
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Structure, Function, and Resistance in Chronic Myeloid Leukemia
- (2014) Jerald Radich CANCER CELL
- Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
- (2014) Paulina Podszywalow-Bartnicka et al. CELL CYCLE
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
- (2014) S. Bibi et al. HAEMATOLOGICA
- Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
- (2014) Yaoyu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells
- (2014) M Nieborowska-Skorska et al. LEUKEMIA
- PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
- (2014) A A Mian et al. LEUKEMIA
- Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
- (2014) M Schmidt et al. LEUKEMIA
- Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
- (2014) Luciene Terezina de Lima et al. MEDICAL ONCOLOGY
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
- (2013) K. Cramer-Morales et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
- (2013) A. Hochhaus et al. BLOOD
- JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
- (2013) W. Warsch et al. BLOOD
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche
- (2013) Koen Schepers et al. Cell Stem Cell
- Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
- (2013) L N Eadie et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
- (2013) M Sigl et al. Blood Cancer Journal
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Role of Epigenetics in Chronic Myeloid Leukemia
- (2013) Katerina Machova Polakova et al. Current Hematologic Malignancy Reports
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2012) Xuelin Huang et al. CANCER
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
- (2012) Sagar Agarwal et al. CURRENT PHARMACEUTICAL DESIGN
- Bone Marrow Microenvironment in Multiple Myeloma Progression
- (2012) S. Manier et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
- (2012) A Slupianek et al. LEUKEMIA
- Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
- (2012) F U Wöhrle et al. LEUKEMIA
- DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells
- (2012) Joana Dinis et al. LEUKEMIA & LYMPHOMA
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2012) Ellen K. Ritchie et al. LEUKEMIA & LYMPHOMA
- Autophagy modulation as a potential therapeutic target for diverse diseases
- (2012) David C. Rubinsztein et al. NATURE REVIEWS DRUG DISCOVERY
- Sirtuins as regulators of metabolism and healthspan
- (2012) Riekelt H. Houtkooper et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias
- (2012) L A Tobin et al. ONCOGENE
- Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation
- (2012) Tomasz Skorski Current Hematologic Malignancy Reports
- Role of STAT3 in Transformation and Drug Resistance in CML
- (2012) Rajesh R. Nair et al. Frontiers in Oncology
- Drug Transporters in Drug Efficacy and Toxicity
- (2011) M.K. DeGorter et al. Annual Review of Pharmacology and Toxicology
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
- (2011) Chor Sang Chim et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells
- (2011) Peter P. Ruvolo et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
- (2011) Hilmar Quentmeier et al. Journal of Hematology & Oncology
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
- (2011) V Grossmann et al. LEUKEMIA
- Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
- (2011) Tomasz Skorski LEUKEMIA & LYMPHOMA
- Mechanisms of resistance to BCR–ABL kinase inhibitors
- (2011) Joana M. Diamond et al. LEUKEMIA & LYMPHOMA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR–ABL1 on the international reporting scale
- (2011) J T Brown et al. Blood Cancer Journal
- MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML
- (2011) Sukanya Suresh et al. Journal of Cell Communication and Signaling
- BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
- (2010) D. W. Sherbenou et al. BLOOD
- BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP
- (2010) Daniela Salles et al. CARCINOGENESIS
- Immunotherapy of chronic myeloid leukemia: present state and future prospects
- (2010) Vladimír Vonka Immunotherapy
- Deactylase inhibition in myeloproliferative neoplasms
- (2010) Sridurga Mithraprabhu et al. INVESTIGATIONAL NEW DRUGS
- Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
- (2010) Torsten Haferlach et al. JOURNAL OF CLINICAL ONCOLOGY
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed
- (2010) Lina Eliasson et al. LEUKEMIA RESEARCH
- A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers
- (2010) Thomas Dunwell et al. Molecular Cancer
- Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents
- (2010) K. Wolanin et al. MOLECULAR CANCER THERAPEUTICS
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Dasatinib in chronic myeloid leukemia: a review
- (2010) Apostolia-Maria Tsimberidou Therapeutics and Clinical Risk Management
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
- (2009) Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Methylation status of RASSF1A in patients with chronic myeloid leukemia
- (2009) Antigoni Avramouli et al. LEUKEMIA RESEARCH
- A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
- (2009) Hugues de Lavallade et al. LEUKEMIA RESEARCH
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
- (2008) Annahita Sallmyr et al. CANCER LETTERS
- BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break Repair
- (2008) K. Cramer et al. CANCER RESEARCH
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
- (2008) Shundong Cang et al. Journal of Hematology & Oncology
- Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
- (2008) Shaoguang Li LEUKEMIA & LYMPHOMA
- Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
- (2008) Nadine N. Bewry et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started